SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

Market sentiment surrounding the Invesco QQQ Trust remains intensely bullish, driven by strong earnings momentum in the semiconductor sector and widespread speculation regarding potential peace talks in the Middle East. Community discourse is highly polarized, with many investors riding the rapid upward trajectory while a vocal segment warns of a potential bubble given the swift pace of recent gains.

SPDR S&P 500 ETF TRUST - SPDR S&P 500 ETF Trust

The S&P 500 continues to rally as markets react to headlines regarding a potential pause in U.S. military efforts in the Strait of Hormuz, with community sentiment deeply polarized between bullish momentum traders chasing AI-driven gains and bearish voices citing concerns over valuation, inflation, and the legitimacy of recent geopolitical announcements.

Advanced Micro Devices, Inc. engages in the semiconductor business. Its products include processors, accelerators, graphics, adaptive SoCs, FPGAs, and SOMs, and software, tools, and apps. The firm offers artificial intelligence, industries, workloads, and gaming solutions. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMD is surging following a blowout earnings report characterized by massive data center growth and strong AI infrastructure demand, with analysts aggressively raising price targets. The community is buzzing with excitement over the stock's parabolic move, fueling intense debate between retail bulls celebrating a "generational" trend and skeptics pointing to soaring valuation multiples and signs of market irrationality.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Investors are actively debating the recent stagnation of NVDA while competitors surge, with many speculating that heavy institutional pinning and capital rotation are suppressing the stock ahead of upcoming earnings. Despite the broader AI sector momentum, the community remains divided between those viewing the current price action as a strategic buying opportunity and those concerned that the stock is losing leadership to memory and CPU-focused chipmakers.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron Technology is trending as retail and institutional investors pile into the stock, fueled by unprecedented demand for memory chips in AI data centers and ongoing excitement over new high-capacity product announcements. While the community is debating whether this parabolic rally represents a sustainable shift in memory sector fundamentals or a classic bubble, many investors are actively discussing potential stock splits and aggressive price targets as Micron hits new highs.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bear 3X ETF

Direxion Daily Semiconductor Bear 3X Shares

Semiconductor investors are engaged in a high-stakes standoff as the market's relentless momentum drives the sector to historic valuation levels, leaving those positioned for a reversal frustrated by persistent after-hours gains. The community is actively debating the sustainability of this melt-up, with many expressing skepticism over disconnected earnings and recycled headlines while others warn that the aggressive nature of leveraged ETFs makes timing a correction particularly dangerous.

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

Super Micro Computer (SMCI) is trending after a significant surge in after-hours trading driven by an earnings beat and strong margin recovery, which has largely eased concerns regarding profitability and prior accounting-related overhangs. The community is actively debating the stock's potential for a massive short squeeze given high short interest, while some remain cautious about management's communication style and ongoing institutional skepticism despite the company's robust data center infrastructure growth.

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

Sandisk is experiencing a massive, parabolic price surge driven by severe NAND flash and DRAM supply shortages, with AI data center demand keeping the memory supercycle in high gear through at least 2027. The community is sharply divided, with bulls celebrating life-changing gains and betting on structural market dominance, while skeptical bears warn of a classic bubble fueled by extreme valuation disconnects and speculative euphoria.

Digi Power X, Inc. is a block chain technology company, which engages in crypto currency mining. It focuses on validation through mining, hosting solutions, and blockchain software solutions. It operates through the following segments: Cryptocurrency Mining, Sales of Energy and Electricity, and Colocation Services. The company was founded on February 18, 2017, and is headquartered in Miami, FL.

Digi Power X Inc. - Ordinary Shares (Sub voting)

Digi Power X is rallying following a landmark 10-year AI data center contract with Cerebras Systems, fueling community optimism about a significant valuation gap and potential for future expansion. While retail investors are actively sharing bullish targets and calling for a short squeeze, some market participants remain cautious due to the stock's historical volatility and speculative nature.

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novo Nordisk is trending as investors pivot toward the potential of its oral Wegovy pipeline, with community sentiment shifting positively following reports of manufacturing scale and a widening efficacy gap between its oral franchise and competitors' small-molecule alternatives. The conversation is primarily focused on the upcoming earnings report and the strategic launch of the Ozempic tablet, with many anticipating that strong volume data will validate a reversal in the stock's recent downtrend.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Organogenesis (ORGO) Projected to Post Earnings on Thursday

Organogenesis (NASDAQ:ORGO) will be releasing its Q1 2026 earnings after the market closes on Thursday, May 7. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-7-organogenesis-holdings-inc-stock...

Organogenesis (NASDAQ:ORGO) Trading Up 1.7% - Time to Buy?

Organogenesis (NASDAQ:ORGO) Shares Up 1.7% - What's Next...

<ul class="summary-bullets"><li>ReNu is a cryopreserved, amniotic suspension allograft.</li><li>The company decided to initiate a rolling application for ReNu following the completion of a meeting with the FDA.</li><li>The treatment received FDA’s Regenerative Medicine Advanced Therapy (RMAT)-designation in 2021.</li></ul> Shares of Organogenesis Holdings Inc. (ORGO) jumped 22% in Monday’s extended trading hours after the company said that it met with the U.S. Food and Drug Administration (FDA), and now plans to initiate seeking approval for its experimental treatment ReNu before the end of December.The company is seeking approval for ReNu in the treatment of knee osteoarthritis pain, a degenerative joint disease that is estimated to affect nearly 31.1 million Americans.ReNu is a cryopreserved, amniotic suspension allograft. It provides anti-inflammatory, growth factor, and cellular components, offering a non-surgical alternative to reduce inflammation, alleviate pain, and enhance joint function. The treatment received FDA’s Regenerative Medicine Advanced Therapy (RMAT)-designation in 2021.<h2 class="st-heading-2">ReNu Application</h2>The company decided to initiate a rolling application for ReNu following the completion of a meeting with the FDA.“We are excited about the outcome of our FDA meeting and reaching this important milestone in the ReNu program. We are pleased the ReNu clinical development program consisting of two large Phase 3 randomized controlled trials (RCT), extensive commercial history and Regenerative Medicine Advanced Therapy (RMAT)-designation is appropriate for BLA submission,” said Patrick Bilbo, Chief Operating Officer of Organogenesis.<h2 class="st-heading-2">How Did Retail Traders React?</h2>On Stocktwits, retail sentiment around ORGO stock stayed within the ‘neutral’ territory while message volume remained at ‘normal’ levels.According to data from Koyfin, the sole analyst covering ORGO rated it ‘Buy’ with a $8 price target that implies a potential upside of about 257% from current trading levels.<a href="https://stocktwits.com/symbol/ORGO">ORGO stock</a> has fallen 42% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/neurocrine-soleno-deal-garners-wall-street-praise/cZJ4wmmRIYV">Neurocrine-Soleno Deal Garners Wall Street Praise — Analyst Applauds Business Development Acumen</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

ORGO Stock Rallies After Hours On Clearing Regulatory Pathway For Pain Relief Treatment 

Organogenesis is seeking approval for ReNu in knee osteoarthritis pain, a degenerative joint disease that is estimated to affect nearly 31.1 million Americans.

Equity

Organogenesis is seeking approval for ReNu in knee osteoarthritis pain, a degenerative joint disease that is estimated to affect nearly 31.1 million Americans.


Organogenesis (NASDAQ:ORGO) Receives "Buy" Rating from BTIG Research

BTIG Research reissued a "buy" rating and issued a $8.00 price objective on shares of Organogenesis in a research report on Thursday...

Assenagon Asset Management S.A. Acquires 680,392 Shares of Organogenesis $ORGO

Assenagon Asset Management S.A. raised its stake in shares of Organogenesis (NASDAQ:ORGO - Free Report) by 14.0% during the fourth quarter, according to its most recent disclosure with the Securities...

Organogenesis $ORGO Shares Acquired by First Light Asset Management LLC

First Light Asset Management LLC lifted its stake in shares of Organogenesis (NASDAQ:ORGO - Free Report) by 10.6% during the 3rd quarter, according to the company in its most recent filing with the...

Insider Buying: Organogenesis (NASDAQ:ORGO) Director Buys 5,000 Shares of Stock

Organogenesis (NASDAQ:ORGO - Get Free Report) Director Arthur Leibowitz purchased 5,000 shares of the stock in a transaction on Monday, March 9th. The stock was acquired at an average cost of $2.68...

Michael Joseph Driscoll Buys 10,000 Shares of Organogenesis (NASDAQ:ORGO) Stock

Organogenesis (NASDAQ:ORGO - Get Free Report) Director Michael Joseph Driscoll purchased 10,000 shares of the business's stock in a transaction on Monday, March 9th. The shares were purchased at an...

Insider Buying: Organogenesis (NASDAQ:ORGO) Director Buys $13,400.00 in Stock

Organogenesis (NASDAQ:ORGO - Get Free Report) Director Arthur Leibowitz acquired 5,000 shares of the firm's stock in a transaction on Monday, March 9th. The shares were acquired at an average price...

Organogenesis (NASDAQ:ORGO) Director Michael Joseph Driscoll Purchases 10,000 Shares of Stock

Organogenesis (NASDAQ:ORGO - Get Free Report) Director Michael Joseph Driscoll bought 10,000 shares of the firm's stock in a transaction dated Monday, March 9th. The stock was purchased at an average...

Organogenesis Holdings, Inc. is a regenerative medical company, which engages in the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical and sports medicine markets. The company was founded in 1985 and is headquartered in Canton, MA.

Organogenesis Holdings Inc - Ordinary Shares - Class A

Still early innings

Overdone

Consolidation due before next leg up

Memory stocks have surged over the past year - is the run overdone or still early innings?

Current Price	$2.59
Prev Close	$2.56
Open	$2.56
Dividend Yield	0.00%
50-Day Moving Average	$2.59
Beta	1.90
Avg. Volume	2.29M
PE Ratio	23.65

52-Week High	$7.08
52-Week Low	$2.21
Market Capitalization	$329.32M
EPS (Annual)	$0.1537
Price to Book	1.10
Revenue Per Employee	$660,619.44

ORGO
Organogenesis Holdings Inc - Ordinary Shares - Class A

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest ORGO News

ORGOOrganogenesis Holdings Inc - Ordinary Shares - Class A